Loading...
Loading...
According to a research report published earlier today, Jefferies has lowered InterMune's
ITMN PT from $10 to $9.
Jefferies said in the report, “Not encouraging SMR score of "3" (low/weak) and ASMR of "4" (minor improvement) for Esbriet in France. Moreover, France/Italy/Spain launches all delayed (likely YE12/2013 from ~2Q12); Esbriet Ph3 data for potential FDA approval also delayed to ~1H14 (from mid-2013). What matters in the end is sales; on delayed launches, smaller # of IPF pts in EU, less pricing power, we view consensus #s (Charts 1&2) need to come down significantly.”
Jefferies maintains its Underperform rating on InterMune, which closed Friday at $15.28.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in